Dale A. Rhoda
Research Subjects
Research Interests
Dale A. Rhoda has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Maria Carolina Danovaro-Holliday
Department of Immunization, Vaccines and Biologicals, World Health Organization, 1211 Geneva, Switzerland
9 shared publications - Caitlin B. Clary
Https://orcid.org
8 shared publications - Erinn M. Hade
Department of Population Health, New York University Grossman School of Medicine , New York, NY 10016
5 shared publications - Felicity T. Cutts
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK
5 shared publications - Jennifer Brustrom
Biostat Global Consulting, 330 Blandford Drive, Worthington, OH 43085, USA
5 shared publications - David M. Murray
Office of Disease Prevention; Division of Program Coordination, Planning, and Strategic Initiatives; Office of the Director, National Institutes of Health, Bethesda, USA
4 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Pan American Health Organization in Revista Panamericana de Salud Pública
- Vol. 50
Assessing vaccination coverage quality in Jamaica during COVID-19 using vcqiR: insights from the 2022 MICS
Objective. This analysis aimed to identify the underlying causes of gaps in routine immunization coverage observed during the COVID-19 pandemic recovery phase by applying the open-source Vaccination Coverage Quality Indicators package in R (vcqiR), addressing limitations in Multiple Indicator Cluster Surveys (MICS) that often omit quality metrics based on detailed vaccination date analysis. Methods. This secondary analysis examined vaccination doses and dates from the Jamaica 2022 MICS (MICS4), for 570 children ages 12–23 months and 24–35 months. Specific indicators included coverage, timeliness, dropouts, and missed opportunities for simultaneous vaccinations (MOSVs). Results. Vaccination coverage for first-year-of-life (1YL) doses exceeded 83% for both age cohorts. Coverage for MMR1 showed substantial catch-up from 12–23 months to 24–35 months, achieving the 95% target. However, MMR2 coverage lagged substantially (37.2% for 12–23 months and 61.9% for 24–35 months), indicating significant attrition in the second year of life. In the 12–23 month cohort, crude coverage of Penta3 was 89%, but only 70% had three valid doses. Most 1YL doses were administered in a timely manner (within 28 days), but premature administration was observed. MOSVs were negligible for 1YL doses but were frequent and mostly uncorrected for 18-month boosters, especially MMR2. Conclusions. The findings complement the MICS4 report and confirm robust early infant immunization delivery but identify programmatic gaps in second year-of-life retention plus the need to strengthen adherence to minimum age interval rules. These results provide detailed evidence necessary to inform targeted interventions and guide the design of future coverage surveys.
- 14 July 2026
- Published by Pan American Health Organization in Revista Panamericana de Salud Pública
- Vol. 50
Open AccessAssessing vaccination coverage quality in Jamaica during COVID-19 using vcqiR: insights from the 2022 MICS
Objective. This analysis aimed to identify the underlying causes of gaps in routine immunization coverage observed during the COVID-19 pandemic recovery phase by applying the open-source Vaccination Coverage Quality Indicators package in R (vcqiR), addressing limitations in Multiple Indicator Cluster Surveys (MICS) that often omit quality metrics based on detailed vaccination date analysis. Methods. This secondary analysis examined vaccination doses and dates from the Jamaica 2022 MICS (MICS4), for 570 children ages 12–23 months and 24–35 months. Specific indicators included coverage, timeliness, dropouts, and missed opportunities for simultaneous vaccinations (MOSVs). Results. Vaccination coverage for first-year-of-life (1YL) doses exceeded 83% for both age cohorts. Coverage for MMR1 showed substantial catch-up from 12–23 months to 24–35 months, achieving the 95% target. However, MMR2 coverage lagged substantially (37.2% for 12–23 months and 61.9% for 24–35 months), indicating significant attrition in the second year of life. In the 12–23 month cohort, crude coverage of Penta3 was 89%, but only 70% had three valid doses. Most 1YL doses were administered in a timely manner (within 28 days), but premature administration was observed. MOSVs were negligible for 1YL doses but were frequent and mostly uncorrected for 18-month boosters, especially MMR2. Conclusions. The findings complement the MICS4 report and confirm robust early infant immunization delivery but identify programmatic gaps in second year-of-life retention plus the need to strengthen adherence to minimum age interval rules. These results provide detailed evidence necessary to inform targeted interventions and guide the design of future coverage surveys.
- Open Access
- 13 July 2026
- Published by Pan American Health Organization in Revista Panamericana de Salud Pública
- Vol. 50, e60
Vaccination Coverage Quality Indicators (VCQI): a flexible open-source tool for survey data analysis.
The World Health Organization (WHO) and Pan American Health Organization (PAHO) make statistical software scripts freely available to conduct standardized analysis of vaccination coverage surveys. The software and accompanying documentation are named the Vaccination Coverage Quality Indicators (VCQI). The software examines data from child vaccination records and caregiver recall to calculate indicators of vaccination access, coverage, continuity, and quality. VCQI produces output tables and figures that may be copied directly into reports and presentations, as well as survey response data sets augmented with child-level outcome indicator variables calculated according to WHO guidance. It can analyze data from routine immunization surveys, post-campaign coverage surveys, and maternal tetanus coverage surveys. VCQI may be used for either the primary analysis of data from new surveys or secondary analysis of earlier surveys. It can analyze data from USAID Demographic and Health Surveys, UNICEF Multiple-Indicator Cluster Surveys, or WHO Expanded Programme on Immunization surveys. Future versions of VCQI may be extended to analyze data from electronic immunization registries. VCQI has been available as a set of Stata scripts since 2015, and as of 2025, the core routine immunization indicators are also available as a new R package named vcqiR. To publicize VCQI's features and capabilities and to celebrate the milestone of R package availability, the authors share this special report to describe the VCQI vision and design, discuss analyses and insights available from it, and map our vision of what the future may hold for flexible standardized analysis of vaccination coverage data.
- 13 July 2026
- Published by Pan American Health Organization in Revista Panamericana de Salud Pública
- Vol. 50, e60
Open AccessVaccination Coverage Quality Indicators (VCQI): a flexible open-source tool for survey data analysis.
The World Health Organization (WHO) and Pan American Health Organization (PAHO) make statistical software scripts freely available to conduct standardized analysis of vaccination coverage surveys. The software and accompanying documentation are named the Vaccination Coverage Quality Indicators (VCQI). The software examines data from child vaccination records and caregiver recall to calculate indicators of vaccination access, coverage, continuity, and quality. VCQI produces output tables and figures that may be copied directly into reports and presentations, as well as survey response data sets augmented with child-level outcome indicator variables calculated according to WHO guidance. It can analyze data from routine immunization surveys, post-campaign coverage surveys, and maternal tetanus coverage surveys. VCQI may be used for either the primary analysis of data from new surveys or secondary analysis of earlier surveys. It can analyze data from USAID Demographic and Health Surveys, UNICEF Multiple-Indicator Cluster Surveys, or WHO Expanded Programme on Immunization surveys. Future versions of VCQI may be extended to analyze data from electronic immunization registries. VCQI has been available as a set of Stata scripts since 2015, and as of 2025, the core routine immunization indicators are also available as a new R package named vcqiR. To publicize VCQI's features and capabilities and to celebrate the milestone of R package availability, the authors share this special report to describe the VCQI vision and design, discuss analyses and insights available from it, and map our vision of what the future may hold for flexible standardized analysis of vaccination coverage data.
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Survey Statistics and Methodology
- Vol. 13 (5) , 587-614
Sample Size Parameters for Vaccination Coverage Cluster Surveys—Insights from Pakistan
Since the 1970s the World Health Organization (WHO) has promoted household surveys with a cluster sample design as an important method to estimate vaccination coverage in low- and middle-income countries. When calculating the survey sample size, planners begin with an educated guess at the outcome proportion and a target precision for the estimate and calculate an effective sample size that would achieve that precision if using a simple random sample. Then they account for correlated outcomes in the cluster sample using an estimated design effect (DEFF) that depends, among other things, on the unknown rate of homogeneity of the outcome as parameterized with an intracluster correlation coefficient (ICC). From the 1970s until 2015, WHO materials suggested that vaccination coverage surveys could be self-weighting and their ICCs would rarely exceed 1/6 or 0.1667. Recommendations drafted in 2015 and finalized in 2018 suggested using a probability sample with survey weights that vary and using a more conservative ICC value of 1/3 = 0.3333 for routine immunization surveys if there was no recent evidence-based estimate available. In this manuscript, we examine variability in survey weights and ICCs for 18 binary outcomes from two recent nationally representative vaccination coverage surveys in Pakistan with 152 districts serving as strata in the sample design, and either 49 or 64 clusters per stratum. The observed values of these parameters are summarized and used to (i) help planners use appropriately small values of ICC when the outcome is expected to have extreme values and (ii) suggest how WHO recommendations on ICC and weights might be refined in a forthcoming update.
- 1 November 2025
- Published by Oxford University Press (OUP) in Journal of Survey Statistics and Methodology
- Vol. 13 (5) , 587-614
Open AccessSample Size Parameters for Vaccination Coverage Cluster Surveys—Insights from Pakistan
Since the 1970s the World Health Organization (WHO) has promoted household surveys with a cluster sample design as an important method to estimate vaccination coverage in low- and middle-income countries. When calculating the survey sample size, planners begin with an educated guess at the outcome proportion and a target precision for the estimate and calculate an effective sample size that would achieve that precision if using a simple random sample. Then they account for correlated outcomes in the cluster sample using an estimated design effect (DEFF) that depends, among other things, on the unknown rate of homogeneity of the outcome as parameterized with an intracluster correlation coefficient (ICC). From the 1970s until 2015, WHO materials suggested that vaccination coverage surveys could be self-weighting and their ICCs would rarely exceed 1/6 or 0.1667. Recommendations drafted in 2015 and finalized in 2018 suggested using a probability sample with survey weights that vary and using a more conservative ICC value of 1/3 = 0.3333 for routine immunization surveys if there was no recent evidence-based estimate available. In this manuscript, we examine variability in survey weights and ICCs for 18 binary outcomes from two recent nationally representative vaccination coverage surveys in Pakistan with 152 districts serving as strata in the sample design, and either 49 or 64 clusters per stratum. The observed values of these parameters are summarized and used to (i) help planners use appropriately small values of ICC when the outcome is expected to have extreme values and (ii) suggest how WHO recommendations on ICC and weights might be refined in a forthcoming update.
- Open Access
Lessons from Recent Measles Post-Campaign Coverage Surveys Worldwide
Background: Measles elimination strategies include supplementary immunization activities (SIAs) to rapidly fill immunity gaps. Post-campaign coverage surveys (PCCSs) are recommended to assess SIA coverage. We characterized selected PCCSs performed following recent SIAs, highlighting specific challenges and strengths, and provide recommendations for improvement. Methods: We extracted national SIA data from the global measles/MR SIA database for the period of 2020–2023 and reviewed PCCS reports available at the World Health Organization headquarters. We extracted selected information on PCCS implementation, including information about the implementer, sampling, and main results. Results: Only 15 of 66 countries (23%) with a national-level SIA performed since 2020 had a PCCS report available. We reviewed those reports, plus six more, following three 2019 SIAs with a delayed PCCS and two PCCSs following large subnational SIAs (Kenya 2021 and Yemen 2023). All 24 PCCS reports available were from Gavi-eligible countries, with 15 from South Saharan Africa (Cameroon, the Democratic Republic of the Congo, and Ethiopia had two PCCSs). Eleven (45.8%) PCCSs were conducted within three months of the end of the SIA. All included sampling information and most had percentage of participation. Description of the interviewers’ profiles varied but was limited. PCCS coverage was lower than administrative data in all but two instances. All PCCSs collected data on previous measles vaccination status that would allow exploring indicators on the SIA reaching previously measles zero-dose children. Of the 12 PCCSs reporting coverage among previously measles zero-dose children, nine reported coverage among this group of more than 50% (range: 12% and 91.6%). Conclusion: Even though a PCCS following an SIA is recommended and a requirement in Gavi-supported countries, most SIAs are not followed by a PCCS and, when performed, the timeliness of survey implementation needs improvement. Recent PCCSs were independently conducted and reports included basic survey information, but analysis and presentation of survey results vary particularly for measles zero-dose-related indicators. More guidance and technical support on how to implement PCCSs, including standardization of reports and more in-depth PCCS analyses, may help improve reporting and use of available PCCS data.
Open AccessLessons from Recent Measles Post-Campaign Coverage Surveys Worldwide
Background: Measles elimination strategies include supplementary immunization activities (SIAs) to rapidly fill immunity gaps. Post-campaign coverage surveys (PCCSs) are recommended to assess SIA coverage. We characterized selected PCCSs performed following recent SIAs, highlighting specific challenges and strengths, and provide recommendations for improvement. Methods: We extracted national SIA data from the global measles/MR SIA database for the period of 2020–2023 and reviewed PCCS reports available at the World Health Organization headquarters. We extracted selected information on PCCS implementation, including information about the implementer, sampling, and main results. Results: Only 15 of 66 countries (23%) with a national-level SIA performed since 2020 had a PCCS report available. We reviewed those reports, plus six more, following three 2019 SIAs with a delayed PCCS and two PCCSs following large subnational SIAs (Kenya 2021 and Yemen 2023). All 24 PCCS reports available were from Gavi-eligible countries, with 15 from South Saharan Africa (Cameroon, the Democratic Republic of the Congo, and Ethiopia had two PCCSs). Eleven (45.8%) PCCSs were conducted within three months of the end of the SIA. All included sampling information and most had percentage of participation. Description of the interviewers’ profiles varied but was limited. PCCS coverage was lower than administrative data in all but two instances. All PCCSs collected data on previous measles vaccination status that would allow exploring indicators on the SIA reaching previously measles zero-dose children. Of the 12 PCCSs reporting coverage among previously measles zero-dose children, nine reported coverage among this group of more than 50% (range: 12% and 91.6%). Conclusion: Even though a PCCS following an SIA is recommended and a requirement in Gavi-supported countries, most SIAs are not followed by a PCCS and, when performed, the timeliness of survey implementation needs improvement. Recent PCCSs were independently conducted and reports included basic survey information, but analysis and presentation of survey results vary particularly for measles zero-dose-related indicators. More guidance and technical support on how to implement PCCSs, including standardization of reports and more in-depth PCCS analyses, may help improve reporting and use of available PCCS data.
- Open Access
Evaluating Scope and Bias of Population-Level Measles Serosurveys: A Systematized Review and Bias Assessment
Background: Measles seroprevalence data have potential to be a useful tool for understanding transmission dynamics and for decision making efforts to strengthen immunization programs. In this study, we conducted a systematized review and bias assessment of all primary data on measles seroprevalence in low- and middle-income countries (as defined by World Bank 2021 income classifications) published from 1962 to 2021. Methods: On 9 March 2022, we searched PubMed for all available data. We included studies containing primary data on measles seroprevalence and excluded studies if they were clinical trials or brief reports, from only health-care workers, suspected measles cases, or only vaccinated persons. We extracted all available information on measles seroprevalence, study design, and seroassay protocol. We conducted a bias assessment based on multiple categories and classified each study as having low, moderate, severe, or critical bias. This review was registered with PROSPERO (CRD42022326075). Results: We identified 221 relevant studies across all World Health Organization regions, decades, and unique age ranges. The overall crude mean seroprevalence across all studies was 78.0% (SD: 19.3%), and the median seroprevalence was 84.0% (IQR: 72.8–91.7%). We classified 80 (36.2%) studies as having severe or critical overall bias. Studies from country-years with lower measles vaccine coverage or higher measles incidence had higher overall bias. Conclusions: While many studies have substantial underlying bias, many studies still provide some insights or data that could be used to inform modelling efforts to examine measles dynamics and programmatic decisions to reduce measles susceptibility.
Open AccessEvaluating Scope and Bias of Population-Level Measles Serosurveys: A Systematized Review and Bias Assessment
Background: Measles seroprevalence data have potential to be a useful tool for understanding transmission dynamics and for decision making efforts to strengthen immunization programs. In this study, we conducted a systematized review and bias assessment of all primary data on measles seroprevalence in low- and middle-income countries (as defined by World Bank 2021 income classifications) published from 1962 to 2021. Methods: On 9 March 2022, we searched PubMed for all available data. We included studies containing primary data on measles seroprevalence and excluded studies if they were clinical trials or brief reports, from only health-care workers, suspected measles cases, or only vaccinated persons. We extracted all available information on measles seroprevalence, study design, and seroassay protocol. We conducted a bias assessment based on multiple categories and classified each study as having low, moderate, severe, or critical bias. This review was registered with PROSPERO (CRD42022326075). Results: We identified 221 relevant studies across all World Health Organization regions, decades, and unique age ranges. The overall crude mean seroprevalence across all studies was 78.0% (SD: 19.3%), and the median seroprevalence was 84.0% (IQR: 72.8–91.7%). We classified 80 (36.2%) studies as having severe or critical overall bias. Studies from country-years with lower measles vaccine coverage or higher measles incidence had higher overall bias. Conclusions: While many studies have substantial underlying bias, many studies still provide some insights or data that could be used to inform modelling efforts to examine measles dynamics and programmatic decisions to reduce measles susceptibility.
- Open Access
- 1 March 2024
- Published by F1000 Research Ltd in Gates Open Research
- Vol. 8, 17
Methods employed in a 2021 population-based serosurvey in Somalia
This paper describes the design and methods of a serosurvey conducted in Somalia in 2021. The study had several concurrent aims: a) to estimate seroprevalence of antibodies to SARS-CoV-2, b) to obtain age-specific data on susceptibility to poliovirus, measles, rubella, diphtheria, and tetanus; and c) to estimate seroprevalence of pathogens causing malaria and neglected tropical diseases. Participants were recruited from persons seeking care at government health facilities as well as friends and family members who accompanied those seeking care. Respondents answered interview questions to establish their demographic profile, their COVID-19 exposure and experience, and, for children, their routine immunization status. Each participant contributed a sample of blood for serum or dried blood spots. Serum samples were analyzed in Somalia for SARS-CoV-2 and dried blood spots were analyzed at the US Centers for Disease Control and Prevention (US CDC) for the other diseases and antigens of interest. This manuscript describes the study design, logistics, laboratory methods, and data management steps used to compile the study dataset. Study results will be reported in a series of manuscripts to follow.
- 1 March 2024
- Published by F1000 Research Ltd in Gates Open Research
- Vol. 8, 17
Open AccessMethods employed in a 2021 population-based serosurvey in Somalia
This paper describes the design and methods of a serosurvey conducted in Somalia in 2021. The study had several concurrent aims: a) to estimate seroprevalence of antibodies to SARS-CoV-2, b) to obtain age-specific data on susceptibility to poliovirus, measles, rubella, diphtheria, and tetanus; and c) to estimate seroprevalence of pathogens causing malaria and neglected tropical diseases. Participants were recruited from persons seeking care at government health facilities as well as friends and family members who accompanied those seeking care. Respondents answered interview questions to establish their demographic profile, their COVID-19 exposure and experience, and, for children, their routine immunization status. Each participant contributed a sample of blood for serum or dried blood spots. Serum samples were analyzed in Somalia for SARS-CoV-2 and dried blood spots were analyzed at the US Centers for Disease Control and Prevention (US CDC) for the other diseases and antigens of interest. This manuscript describes the study design, logistics, laboratory methods, and data management steps used to compile the study dataset. Study results will be reported in a series of manuscripts to follow.
- Open Access
A Practical Guide to Pilot Testing Community-Based Vaccination Coverage Surveys
Pilot testing is crucial when preparing any community-based vaccination coverage survey. In this paper, we use the term pilot test to mean informative work conducted before a survey protocol has been finalized for the purpose of guiding decisions about how the work will be conducted. We summarize findings from seven pilot tests and provide practical guidance for piloting similar studies. We selected these particular pilots because they are excellent models of preliminary efforts that informed the refinement of data collection protocols and instruments. We recommend survey coordinators devote time and budget to identify aspects of the protocol where testing could mitigate project risk and ensure timely assessment yields, credible estimates of vaccination coverage and related indicators. We list specific items that may benefit from pilot work and provide guidance on how to prioritize what to pilot test when resources are limited.
Open AccessA Practical Guide to Pilot Testing Community-Based Vaccination Coverage Surveys
Pilot testing is crucial when preparing any community-based vaccination coverage survey. In this paper, we use the term pilot test to mean informative work conducted before a survey protocol has been finalized for the purpose of guiding decisions about how the work will be conducted. We summarize findings from seven pilot tests and provide practical guidance for piloting similar studies. We selected these particular pilots because they are excellent models of preliminary efforts that informed the refinement of data collection protocols and instruments. We recommend survey coordinators devote time and budget to identify aspects of the protocol where testing could mitigate project risk and ensure timely assessment yields, credible estimates of vaccination coverage and related indicators. We list specific items that may benefit from pilot work and provide guidance on how to prioritize what to pilot test when resources are limited.
- Open Access
Understanding COVID-19 Vaccine Acceptance among Latin American Health Workers: Implications for Designing Interventions
Health workers (HWs) have a key role in promoting vaccine acceptance. This study draws on the Behavioral and Social Drivers of Vaccination (BeSD) model and our team’s investigation of vaccine hesitancy in a sample of 1197 HWs across 14 Caribbean countries in 2021. We conducted a cross-sectional Internet survey of 6718 HWs across 16 countries in Latin America in spring 2022, after the COVID-19 vaccine had recently become widely available in the region. The survey assessed HWs’ attitudes regarding COVID-19 vaccines and vaccines in general. As a proxy measure of COVID-19 vaccine acceptance, we used the willingness to recommend the COVID-19 vaccine to eligible people. Ninety-seven percent of respondents were COVID-19 vaccine acceptant. Although nearly all respondents felt that the COVID-19 vaccine was safe and effective, 59% expressed concerns about potential adverse effects. Despite uniformly high acceptance of the COVID-19 vaccine overall and across Latin American subregions, acceptance differed by sex, HW profession, and COVID-19 history. Social processes, including actions and opinions of friends, family, and colleagues; actions and opinions of religious leaders; and information seen on social networks shaped many respondents’ opinions of vaccines, and the magnitude of these effects differed across both demographic and geographic subgroups. Information campaigns designed for HWs should underscore the importance of vaccine safety. Messages should be tailored to specific audiences according to the information source each is most likely to consult and trust.
Open AccessUnderstanding COVID-19 Vaccine Acceptance among Latin American Health Workers: Implications for Designing Interventions
Health workers (HWs) have a key role in promoting vaccine acceptance. This study draws on the Behavioral and Social Drivers of Vaccination (BeSD) model and our team’s investigation of vaccine hesitancy in a sample of 1197 HWs across 14 Caribbean countries in 2021. We conducted a cross-sectional Internet survey of 6718 HWs across 16 countries in Latin America in spring 2022, after the COVID-19 vaccine had recently become widely available in the region. The survey assessed HWs’ attitudes regarding COVID-19 vaccines and vaccines in general. As a proxy measure of COVID-19 vaccine acceptance, we used the willingness to recommend the COVID-19 vaccine to eligible people. Ninety-seven percent of respondents were COVID-19 vaccine acceptant. Although nearly all respondents felt that the COVID-19 vaccine was safe and effective, 59% expressed concerns about potential adverse effects. Despite uniformly high acceptance of the COVID-19 vaccine overall and across Latin American subregions, acceptance differed by sex, HW profession, and COVID-19 history. Social processes, including actions and opinions of friends, family, and colleagues; actions and opinions of religious leaders; and information seen on social networks shaped many respondents’ opinions of vaccines, and the magnitude of these effects differed across both demographic and geographic subgroups. Information campaigns designed for HWs should underscore the importance of vaccine safety. Messages should be tailored to specific audiences according to the information source each is most likely to consult and trust.
- Open Access
- 25 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0269066
Multilevel analysis of predictors of multiple indicators of childhood vaccination in Nigeria
Background: Substantial inequalities exist in childhood vaccination coverage levels. To increase vaccine uptake, factors that predict vaccination coverage in children should be identified and addressed. Methods: Using data from the 2018 Nigeria Demographic and Health Survey and geospatial data sets, we fitted Bayesian multilevel binomial and multinomial logistic regression models to analyse independent predictors of three vaccination outcomes: receipt of the first dose of Pentavalent vaccine (containing diphtheria-tetanus-pertussis, Hemophilus influenzae type B and Hepatitis B vaccines) (PENTA1) (n = 6059) and receipt of the third dose having received the first (PENTA3/1) (n = 3937) in children aged 12–23 months, and receipt of measles vaccine (MV) (n = 11839) among children aged 12–35 months. Results: Factors associated with vaccination were broadly similar for documented versus recall evidence of vaccination. Based on any evidence of vaccination, we found that health card/document ownership, receipt of vitamin A and maternal educational level were significantly associated with each outcome. Although the coverage of each vaccine dose was higher in urban than rural areas, urban residence was not significant in multivariable analyses that included travel time. Indicators relating to socio-economic status, as well as ethnic group, skilled birth attendance, lower travel time to the nearest health facility and problems seeking health care were significantly associated with both PENTA1 and MV. Maternal religion was related to PENTA1 and PENTA3/1 and maternal age related to MV and PENTA3/1; other significant variables were associated with one outcome each. Substantial residual community level variances in different strata were observed in the fitted models for each outcome. Conclusion: Our analysis has highlighted socio-demographic and health care access factors that affect not only beginning but completing the vaccination series in Nigeria. Other factors not measured by the DHS such as health service quality and community attitudes should also be investigated and addressed to tackle inequities in coverage.
- 25 May 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (5) , e0269066
Open AccessMultilevel analysis of predictors of multiple indicators of childhood vaccination in Nigeria
Background: Substantial inequalities exist in childhood vaccination coverage levels. To increase vaccine uptake, factors that predict vaccination coverage in children should be identified and addressed. Methods: Using data from the 2018 Nigeria Demographic and Health Survey and geospatial data sets, we fitted Bayesian multilevel binomial and multinomial logistic regression models to analyse independent predictors of three vaccination outcomes: receipt of the first dose of Pentavalent vaccine (containing diphtheria-tetanus-pertussis, Hemophilus influenzae type B and Hepatitis B vaccines) (PENTA1) (n = 6059) and receipt of the third dose having received the first (PENTA3/1) (n = 3937) in children aged 12–23 months, and receipt of measles vaccine (MV) (n = 11839) among children aged 12–35 months. Results: Factors associated with vaccination were broadly similar for documented versus recall evidence of vaccination. Based on any evidence of vaccination, we found that health card/document ownership, receipt of vitamin A and maternal educational level were significantly associated with each outcome. Although the coverage of each vaccine dose was higher in urban than rural areas, urban residence was not significant in multivariable analyses that included travel time. Indicators relating to socio-economic status, as well as ethnic group, skilled birth attendance, lower travel time to the nearest health facility and problems seeking health care were significantly associated with both PENTA1 and MV. Maternal religion was related to PENTA1 and PENTA3/1 and maternal age related to MV and PENTA3/1; other significant variables were associated with one outcome each. Substantial residual community level variances in different strata were observed in the fitted models for each outcome. Conclusion: Our analysis has highlighted socio-demographic and health care access factors that affect not only beginning but completing the vaccination series in Nigeria. Other factors not measured by the DHS such as health service quality and community attitudes should also be investigated and addressed to tackle inequities in coverage.
- Open Access
- 3 February 2022
- Published by Springer Nature in BMC Public Health
- Vol. 22 (1) , 1-16
Who gets vaccinated in a measles-rubella campaign in Nepal?: results from a post-campaign coverage survey
Background: Following the 2015 earthquake, a measles-rubella (MR) supplementary immunization activity (SIA), in four phases, was implemented in Nepal in 2015–2016. A post-campaign coverage survey (PCCS) was then conducted in 2017 to assess SIA performance and explore factors that were associated with vaccine uptake. Methods: A household survey using stratified multi-stage probability sampling was conducted to assess coverage for a MR dose in the 2015–2016 SIA in Nepal. Logistic regression was then used to identify factors related to vaccine uptake. Results: Eleven thousand two hundred fifty-three households, with 4870 eligible children provided information on vaccination during the 2015–2016 MR SIA. Overall coverage of measles-rubella vaccine was 84.7% (95% CI: 82.0–87.0), but varied between 77.5% (95% CI: 72.0, 82.2) in phase-3, of 21 districts vaccinated in Feb-Mar 2016, to 97.7% (CI: 95.4, 98.9) in phase-4, of the last seven mountainous districts vaccinated in Mar-Apr 2016. Coverage in rural areas was higher at 85.6% (CI: 81.9, 88.8) than in urban areas at 79.0% (CI: 75.5, 82.1). Of the 4223 children whose caregivers knew about the SIA, 96.5% received the MR dose and of the 647 children whose caregivers had not heard about the campaign, only 1.8% received the MR dose. Conclusions: The coverage in the 2015–2016 MR SIA in Nepal varied by geographical region with rural areas achieving higher coverage than urban areas. The single most important predictor of vaccination was the caregiver being informed in advance about the vaccination campaign. Enhanced efforts on social mobilization for vaccination have been used in Nepal since this survey, notably for the most recent 2020 MR campaign.
- 3 February 2022
- Published by Springer Nature in BMC Public Health
- Vol. 22 (1) , 1-16
Open AccessWho gets vaccinated in a measles-rubella campaign in Nepal?: results from a post-campaign coverage survey
Background: Following the 2015 earthquake, a measles-rubella (MR) supplementary immunization activity (SIA), in four phases, was implemented in Nepal in 2015–2016. A post-campaign coverage survey (PCCS) was then conducted in 2017 to assess SIA performance and explore factors that were associated with vaccine uptake. Methods: A household survey using stratified multi-stage probability sampling was conducted to assess coverage for a MR dose in the 2015–2016 SIA in Nepal. Logistic regression was then used to identify factors related to vaccine uptake. Results: Eleven thousand two hundred fifty-three households, with 4870 eligible children provided information on vaccination during the 2015–2016 MR SIA. Overall coverage of measles-rubella vaccine was 84.7% (95% CI: 82.0–87.0), but varied between 77.5% (95% CI: 72.0, 82.2) in phase-3, of 21 districts vaccinated in Feb-Mar 2016, to 97.7% (CI: 95.4, 98.9) in phase-4, of the last seven mountainous districts vaccinated in Mar-Apr 2016. Coverage in rural areas was higher at 85.6% (CI: 81.9, 88.8) than in urban areas at 79.0% (CI: 75.5, 82.1). Of the 4223 children whose caregivers knew about the SIA, 96.5% received the MR dose and of the 647 children whose caregivers had not heard about the campaign, only 1.8% received the MR dose. Conclusions: The coverage in the 2015–2016 MR SIA in Nepal varied by geographical region with rural areas achieving higher coverage than urban areas. The single most important predictor of vaccination was the caregiver being informed in advance about the vaccination campaign. Enhanced efforts on social mobilization for vaccination have been used in Nepal since this survey, notably for the most recent 2020 MR campaign.